P2RY12 and peripheral arterial disease: Aspirin is considered the cornerstone of secondary prevention based on numerous studies consistently demonstrating that aspirin alone or in combination with P2Y12 inhibition can significantly reduce ischemic events and cardiovascular (CV) deaths resulting from acute coronary syndrome (ACS) (Mehta et al., 2010), stable coronary artery disease (CAD) (Antithrombotic Trialists’ Collaboration, 2002; Udell et al., 2016), and peripheral artery disease (PAD) (Beiswenger et al., 2018).